Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

University of British Columbia

$474,300.00

Blood based biomarker for the early detection of recurrent oropharyngeal cancer

EF 2023-24

Résumé
Oropharyngeal cancer is a type of head and neck cancer in which cancer cells are detected in an area of your throat called your oropharynx. This type of cancer can be caused by tobacco and alcohol use as well as HPV infection. There has been an increase in HPV related OPC that has been associated with a younger population (under 60 years of age). Despite a good response to treatment some people with OPC will have recurrent disease. These recurrences are often hard to detect and are therefore not diagnosed until the disease is at an advanced stage. We have developed a simple blood test that can be used to detect recurrent OPC before it is clinically evident. Our objective is to further optimize this test to facilitate commercialization in order for the test to be used routinely in the clinic. Earlier detection of recurrent disease will increase survival rates for people diagnosed with OPC.
Programme
Project Grant
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
488232
Name
Garnis Cathie
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Commercialization
Projecttitle
Blood based biomarker for the early detection of recurrent oropharyngeal cancer
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$474,300
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Biomarker; Head And Neck Cancer; Microrna; Oropharyngeal Cancer; Qrtpcr
Abstract
Oropharyngeal cancer is a type of head and neck cancer in which cancer cells are detected in an area of your throat called your oropharynx. This type of cancer can be caused by tobacco and alcohol use as well as HPV infection. There has been an increase in HPV related OPC that has been associated with a younger population (under 60 years of age). Despite a good response to treatment some people with OPC will have recurrent disease. These recurrences are often hard to detect and are therefore not diagnosed until the disease is at an advanced stage. We have developed a simple blood test that can be used to detect recurrent OPC before it is clinically evident. Our objective is to further optimize this test to facilitate commercialization in order for the test to be used routinely in the clinic. Earlier detection of recurrent disease will increase survival rates for people diagnosed with OPC.
Competitiondate
202309
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Garnis, Cathie
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $474,300~ $0~